analysis

Oracle (NYSE:) is at a critical juncture as it navigates the evolving AI landscape. The company’s strategic positioning within the…

By Chad Terhune (Reuters) -Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were…

President Joe Biden is running for re-election, and his potential second term could significantly impact various sectors, including energy. Understanding…

Last year, while the United Arab Emirates oversaw a historic agreement to fight the climate crisis, it was brokering deals…

Goldman Sachs (NYSE:) has analyzed NTPC’s fourth-quarter performance for FY24, noting an adjusted consolidated profit after tax (PAT) of Rs…

By Maggie Fick LONDON (Reuters) – Novo Nordisk (NYSE:)’s Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight…